Synthace Chief Science Officer to Speak at BioProcess International US West

Synthace Senior Executive to address: Closing the loop in bioprocessing with connected lab automation and data integration

LONDON 14 March 2019 - Markus Gershater, Chief Scientific Officer, Synthace will be speaking at BioProcess International US West Conference on Thursday, March 14, 2019. The conference is being held from March 11-14, 2019 at the Santa Clara Convention Center, Santa Clara, California, USA. Synthace Ltd, is the leading start-up behind the transformative cloud software platform for automating and improving the success rate of biological research and development.

 

During his address, Markus will discuss how software can be used to unlock the analytics bottleneck in upstream bioprocessing in both traditional biologics and cell and gene therapies. The automation of off-line assays and their integration with online data streams will unlock more robust processes and facilitate a move towards full design space-automation.

 

Markus co-founded Synthace after working as a Research Associate in Synthetic Biology at University College London where he developed novel biosynthesis methods using pathway engineering. Before UCL, he was a Biotransformation Scientist at Novacta Biosystems working as part of the industrial biotechnology group that conducted more than 90 contract research projects for over 20 clients. Markus has a Ph.D. in Plant Biochemistry from Durham.

 

In December 2018, Synthace closed its $25.6m Series B financing round, focusing on accelerated product development and building upon its cell and gene therapy customer base to drive global awareness of its solutions. Synthace is at the forefront of the global conversation around building and designing tools that will replace artisanal laboratory processes and initiating the ability to engineer biology. In October 2018 the company launched its industry-leading white paper on this topic, Computer Aided Biology: Delivering Biotechnology in the 21st Century, which provides the most complete vision for how biological research will be transformed by an emerging ecosystem of cloud-connected and digitally empowered research tools that augment human capabilities, accelerating the transition of biology towards becoming an engineering discipline. Only by connecting the entire suite of the digital and physical ecosystem, and enabling an integrated loop, will scientists be able to address the challenges of 21st-century biology.

 

"I am delighted to be speaking at the BioProcess International US West Conference," said Markus Gershater, Chief Scientific Officer, Synthace.

 

Gershater concluded" We are at a pivotal point in the development and use of biotechnology, and only truly disruptive technology will fundamentally change the lab of the future. The BPI conference is an excellent opportunity to engage with leading industry thinkers and partners, and I look forward to dynamic conversations on how we can utilise biotechnology to change the world."

 

Tweet this: Attending @bioprocess365 BPI West? Make sure to attend @markusgershater discussion on March 14th as he chats about closing the loop in #bioprocessing w/connected lab #automation & data integration #biotech #pharma #biology #digitaltransformation #synbio https://bit.ly/2TuvySt

 

 

Follow Synthace

Synthace Blog 

Join the Twitter Conversation 

Join us on LinkedIn

 

 

About Synthace

Based in London, Synthace is developing Antha, a language and software platform specifically for biology that lets researchers aim higher and achieve better results, faster. Antha is designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment. With customers across pharma, agritech and industrial biotechnology Synthace has been recognised by the World Economic Forum as a Technology Pioneer that is helping shape the Fourth Industrial Revolution – a technological revolution that will fundamentally alter the way we live, work and relate to one another. For more information, visit: www.synthace.com. 

 

Press Enquiries

c.glymph@synthace.com
07867488769